https://www.selleckchem.com/pr....oducts/tauroursodeox
0001) or DTX-sHDL (MS = 28 days, p less then 0.0001). Two of seven mice treated with DTX-sHDL/CpG experienced complete tumor regression. None of the mice experienced any systemic toxicity as indicated by body weight maintenance and normal serum enzyme and protein levels. In summary, we have demonstrated that chemo- and immunotherapies can be co-loaded into sHDLs, delivered locally to the tumor, and can be used to improve survival outcomes significantly compared to chemotherapy alone.Interstitial lung disease (ILD) seem
Like
Comment
Share
